Animal Models to Evaluate Anti-infective Pharmacodynamics

A marine microbiome antifungal targets urgent-threat drug-resistant fungi

“…We next explored in vivo efficacy using the U.S. Food and Drug Administration (FDA) standard fungal model for invasive candidiasis. This neutropenic mouse model involves Candida injection into the bloodstream and assessment of treatment response by viable fungal burden in the kidney (26,27). Mice injected with a panresistant strain of C. auris (strain B11211) received five doses of turbinmicin, increasing by twofold and administered every 6 hours (0.25 to 4 mg/kg every 6 hours) over a 24-hour treatment period.…”